Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Revenues:
Clinical treatment programs	$ 15	$ 47	$ 54	$ 83
Total revenues	15	47	54	83
Costs and expenses:
Production costs	290	507	558	879
Research and development	900	2,439	1,902	5,113
General and administrative	1,639	2,002	4,087	3,915
Total costs and expenses	2,829	4,948	6,547	9,907
Operating loss	(2,814)	(4,901)	(6,493)	(9,824)
Interest expense				(2)
Interest and other income/expense	55	56	116	162
Insurance proceeds from legal settlement, net	1,436		1,436
Gain (Loss) on sales of short term marketable securities	20		(87)
Gain from sale of income tax net operating losses			1,561	1,374
Net loss	(1,303)	(4,845)	(3,467)	(8,290)
Other comprehensive income (loss):
Reclassification adjustments for loss on sales of short term marketable securities included in net loss			87
Unrealized gain (loss) on marketable securities	38	(137)	97	(26)
Net comprehensive loss	$ (1,265)	$ (4,982)	$ (3,283)	$ (8,316)
Basic and diluted loss per share (in dollars per share)	$ (0.01)	$ (0.02)	$ (0.01)	$ (0.04)
Weighted average shares outstanding, basic and diluted (in shares)	248,008,113	236,149,999	247,786,026	224,954,200